Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement

Bone Marrow Transplantation

Volumn 49, Issue 3, 2014, Pages 434-439

  Girnius, S ^a,b   Seldin, D C ^a,b   Meier Ewert, H K ^a,b   Sloan, J M ^a,b   Quillen, K ^a,b   Ruberg, F L ^a,b   Berk, J L ^a,b   Doros, G ^c   Sanchorawala, V ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

AL amyloidosis; cardiac biomarkers; cardiac involvement; melphalan; SCT

Indexed keywords

BORTEZOMIB; BRAIN NATRIURETIC PEPTIDE; MELPHALAN; TROPONIN I; BIOLOGICAL MARKER;

ABDOMINAL BLEEDING; ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FUNCTIONAL ASSESSMENT; HEART AMYLOIDOSIS; HEART VENTRICLE ARRHYTHMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; YOUNG ADULT; CLINICAL TRIAL; COMPLICATION; CYTOLOGY; FOLLOW UP; HEART DISEASES; HEMATOPOIETIC STEM CELL; KAPLAN MEIER METHOD; METABOLISM; PATHOPHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STEM CELL TRANSPLANTATION; TIME; TREATMENT OUTCOME;

AGED; AMYLOIDOSIS; BIOMARKERS; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HEMATOPOIETIC STEM CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELPHALAN; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TIME FACTORS; TREATMENT OUTCOME; TROPONIN I;

EID: 84904243350     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.192     Document Type: Article

References (18)

1. Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998; 91: 141-157.
2. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751-3757.
3. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881-1887.
4. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30: 989-995.
5. Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P, Sarais G et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 2010; 116: 3426-3430.
6. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013; 121: 3420-3427.
7. Madan S, Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amy-loidosis with cardiac involvement. Blood 2012; 119: 1117-1122.
8. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319-328.
9. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79-108.
10. Masson S, Vago T, Baldi G, Salio M, De Angelis N, Nicolis E et al. Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. Clin Chem Lab Med 2002; 40: 761-763.
11. McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003; 4: 72-80.
12. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85-93.
13. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011; 118: 4346-4352.
14. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012; 30: 4541-4549.
15. Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Dingli D, Leung N et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant 2013; 48: 557-561.
16. Girnius S, Seldin DC, Cibeira MT, Sanchorawala V. New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation. J Clin Oncol 2013; 31: 2749-2750.
17. Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 2005; 36: 597-600.
18. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 1083-1093.